Difference between revisions of "Gastric cancer - historical"
Warner-admin (talk | contribs) m (Text replacement - "Comparative Efficacy" to "Comparative Efficacy") |
Warner-admin (talk | contribs) m (Text replacement - "http://ascopubs.org" to "https://ascopubs.org") |
||
Line 149: | Line 149: | ||
| style="background-color:#ffffbf" |Seems not superior | | style="background-color:#ffffbf" |Seems not superior | ||
|- | |- | ||
− | |[ | + | |[https://ascopubs.org/doi/abs/10.1200/JCO.1991.9.5.827 Wils et al. 1991] |
| style="background-color:#1a9851" |Phase III (C) | | style="background-color:#1a9851" |Phase III (C) | ||
|[[#FAMTX|FAMTX]] | |[[#FAMTX|FAMTX]] | ||
Line 174: | Line 174: | ||
# MacDonald JS, Woolley PV, Smythe T, Ueno W, Hoth D, Schein PS. 5-fluorouracil, adriamycin, and mitomycin-C (FAM) combination chemotherapy in the treatment of advanced gastric cancer. Cancer. 1979 Jul;44(1):42-7. [https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142(197907)44:1%3C42::AID-CNCR2820440108%3E3.0.CO;2-X link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/455263 PubMed] | # MacDonald JS, Woolley PV, Smythe T, Ueno W, Hoth D, Schein PS. 5-fluorouracil, adriamycin, and mitomycin-C (FAM) combination chemotherapy in the treatment of advanced gastric cancer. Cancer. 1979 Jul;44(1):42-7. [https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142(197907)44:1%3C42::AID-CNCR2820440108%3E3.0.CO;2-X link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/455263 PubMed] | ||
# Cullinan SA, Moertel CG, Fleming TR, Rubin JR, Krook JE, Everson LK, Windschitl HE, Twito DI, Marschke RF, Foley JF, Pfeifle DM, Barlow JF. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma: fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA. 1985 Apr 12;253(14):2061-7. [https://jamanetwork.com/journals/jama/fullarticle/397816 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/2579257 PubMed] | # Cullinan SA, Moertel CG, Fleming TR, Rubin JR, Krook JE, Everson LK, Windschitl HE, Twito DI, Marschke RF, Foley JF, Pfeifle DM, Barlow JF. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma: fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA. 1985 Apr 12;253(14):2061-7. [https://jamanetwork.com/journals/jama/fullarticle/397816 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/2579257 PubMed] | ||
− | # Wils JA, Klein HO, Wagener DJ, Bleiberg H, Reis H, Korsten F, Conroy T, Fickers M, Leyvraz S, Buyse M, Duez N. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol. 1991 May;9(5):827-31. [ | + | # Wils JA, Klein HO, Wagener DJ, Bleiberg H, Reis H, Korsten F, Conroy T, Fickers M, Leyvraz S, Buyse M, Duez N. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol. 1991 May;9(5):827-31. [https://ascopubs.org/doi/abs/10.1200/JCO.1991.9.5.827 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/2016625 PubMed] |
# Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC, Kang YK, Shin DB, Kim HT, Kim HJ, Kang WK, Suh CI, Bang YJ. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer. 1993 Jun 15;71(12):3813-8. [https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142%2819930615%2971%3A12%3C3813%3A%3AAID-CNCR2820711205%3E3.0.CO%3B2-5 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/8508349 PubMed] | # Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC, Kang YK, Shin DB, Kim HT, Kim HJ, Kang WK, Suh CI, Bang YJ. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer. 1993 Jun 15;71(12):3813-8. [https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142%2819930615%2971%3A12%3C3813%3A%3AAID-CNCR2820711205%3E3.0.CO%3B2-5 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/8508349 PubMed] | ||
# Kim SY, Park HC, Yoon C, Yoon HJ, Choi YM, Cho KS. OK-432 and 5-fluorouracil, doxorubicin, and mitomycin C (FAM-P) versus FAM chemotherapy in patients with curatively resected gastric carcinoma: a randomized Phase III trial. Cancer. 1998 Nov 15;83(10):2054-9. [https://onlinelibrary.wiley.com/doi/full/10.1002/%28SICI%291097-0142%2819981115%2983%3A10%3C2054%3A%3AAID-CNCR2%3E3.0.CO%3B2-1 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/9827708 PubMed] | # Kim SY, Park HC, Yoon C, Yoon HJ, Choi YM, Cho KS. OK-432 and 5-fluorouracil, doxorubicin, and mitomycin C (FAM-P) versus FAM chemotherapy in patients with curatively resected gastric carcinoma: a randomized Phase III trial. Cancer. 1998 Nov 15;83(10):2054-9. [https://onlinelibrary.wiley.com/doi/full/10.1002/%28SICI%291097-0142%2819981115%2983%3A10%3C2054%3A%3AAID-CNCR2%3E3.0.CO%3B2-1 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/9827708 PubMed] | ||
Line 191: | Line 191: | ||
!style="width: 25%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | !style="width: 25%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |[ | + | |[https://ascopubs.org/doi/abs/10.1200/JCO.1991.9.5.827 Wils et al. 1991] |
| style="background-color:#1a9851" |Phase III (E) | | style="background-color:#1a9851" |Phase III (E) | ||
|[[#FAM|FAM]] | |[[#FAM|FAM]] | ||
| style="background-color:#1a9850" |Superior OS | | style="background-color:#1a9850" |Superior OS | ||
|- | |- | ||
− | |[ | + | |[https://ascopubs.org/doi/abs/10.1200/JCO.1992.10.4.541 Kelsen et al. 1992] |
| style="background-color:#1a9851" |Phase III (E) | | style="background-color:#1a9851" |Phase III (E) | ||
|EAP | |EAP | ||
| style="background-color:#ffffbf" |Seems not superior | | style="background-color:#ffffbf" |Seems not superior | ||
|- | |- | ||
− | |[ | + | |[https://ascopubs.org/doi/10.1200/JCO.1997.15.1.261 Webb et al. 1997] |
| style="background-color:#1a9851" |Phase III (C) | | style="background-color:#1a9851" |Phase III (C) | ||
|[[Gastric_cancer#ECF_3|ECF]] | |[[Gastric_cancer#ECF_3|ECF]] | ||
| style="background-color:#d73027" |Inferior OS | | style="background-color:#d73027" |Inferior OS | ||
|- | |- | ||
− | |[ | + | |[https://ascopubs.org/doi/full/10.1200/JCO.2000.18.14.2648 Vanhoefer et al. 2000 (EORTC 40902)] |
| style="background-color:#1a9851" |Phase III (C) | | style="background-color:#1a9851" |Phase III (C) | ||
|1. ELF<br> 2. FUP | |1. ELF<br> 2. FUP | ||
Line 218: | Line 218: | ||
===References=== | ===References=== | ||
− | # Wils JA, Klein HO, Wagener DJ, Bleiberg H, Reis H, Korsten F, Conroy T, Fickers M, Leyvraz S, Buyse M, Duez N. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol. 1991 May;9(5):827-31. [ | + | # Wils JA, Klein HO, Wagener DJ, Bleiberg H, Reis H, Korsten F, Conroy T, Fickers M, Leyvraz S, Buyse M, Duez N. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol. 1991 May;9(5):827-31. [https://ascopubs.org/doi/abs/10.1200/JCO.1991.9.5.827 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/2016625 PubMed] |
− | # Kelsen D, Atiq OT, Saltz L, Niedzwiecki D, Ginn D, Chapman D, Heelan R, Lightdale C, Vinciguerra V, Brennan M. FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol. 1992 Apr;10(4):541-8. [ | + | # Kelsen D, Atiq OT, Saltz L, Niedzwiecki D, Ginn D, Chapman D, Heelan R, Lightdale C, Vinciguerra V, Brennan M. FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol. 1992 Apr;10(4):541-8. [https://ascopubs.org/doi/abs/10.1200/JCO.1992.10.4.541 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/1548519 PubMed] |
− | # Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, Hughes M, Mansi J, Findlay M, Hill A, Oates J, Nicolson M, Hickish T, O'Brien M, Iveson T, Watson M, Underhill C, Wardley A, Meehan M. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997 Jan;15(1):261-7. [ | + | # Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, Hughes M, Mansi J, Findlay M, Hill A, Oates J, Nicolson M, Hickish T, O'Brien M, Iveson T, Watson M, Underhill C, Wardley A, Meehan M. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997 Jan;15(1):261-7. [https://ascopubs.org/doi/10.1200/JCO.1997.15.1.261 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/8996151 PubMed] |
## '''Update:''' Waters JS, Norman A, Cunningham D, Scarffe JH, Webb A, Harper P, Joffe JK, Mackean M, Mansi J, Leahy M, Hill A, Oates J, Rao S, Nicolson M, Hickish T. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer. 1999 Apr;80(1-2):269-72. [https://www.nature.com/articles/6690350 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363002/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/10390007 PubMed] | ## '''Update:''' Waters JS, Norman A, Cunningham D, Scarffe JH, Webb A, Harper P, Joffe JK, Mackean M, Mansi J, Leahy M, Hill A, Oates J, Rao S, Nicolson M, Hickish T. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer. 1999 Apr;80(1-2):269-72. [https://www.nature.com/articles/6690350 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363002/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/10390007 PubMed] | ||
− | # '''EORTC 40902:''' Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E, Planker M, Santos JG, Piedbois P, Paillot B, Bodenstein H, Schmoll HJ, Bleiberg H, Nordlinger B, Couvreur ML, Baron B, Wils JA. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol. 2000 Jul;18(14):2648-57. [ | + | # '''EORTC 40902:''' Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E, Planker M, Santos JG, Piedbois P, Paillot B, Bodenstein H, Schmoll HJ, Bleiberg H, Nordlinger B, Couvreur ML, Baron B, Wils JA. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol. 2000 Jul;18(14):2648-57. [https://ascopubs.org/doi/full/10.1200/JCO.2000.18.14.2648 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/10894863 PubMed] |
==FEMTX {{#subobject:412e7b|Regimen=1}}== | ==FEMTX {{#subobject:412e7b|Regimen=1}}== |
Revision as of 15:35, 23 June 2019
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Is there a regimen missing from this list? See the main gastric cancer page for current regimens.
8 regimens on this page
9 variants on this page
|
Adjuvant therapy
Doxifluridine & Mitomycin
back to top |
Regimen
Study | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|
Kang et al. 2013 (AMC0201) | Phase III (C) | MFP | Seems not superior |
Kang et al. 2013 (AMC0101) | Phase III (C) | iceMFP | Seems to have inferior OS |
Preceding treatment
Chemotherapy
References
- AMC0201: Kang YK, Chang HM, Yook JH, Ryu MH, Park I, Min YJ, Zang DY, Kim GY, Yang DH, Jang SJ, Park YS, Lee JL, Kim TW, Oh ST, Park BK, Jung HY, Kim BS. Adjuvant chemotherapy for gastric cancer: a randomised phase 3 trial of mitomycin-C plus either short-term doxifluridine or long-term doxifluridine plus cisplatin after curative D2 gastrectomy (AMC0201). Br J Cancer. 2013 Apr 2;108(6):1245-51. Epub 2013 Feb 28. link to original article link to PMC article PubMed
- AMC0101: Kang YK, Yook JH, Chang HM, Ryu MH, Yoo C, Zang DY, Lee JL, Kim TW, Yang DH, Jang SJ, Park YS, Lee YJ, Jung HY, Kim JH, Kim BS. Enhanced efficacy of postoperative adjuvant chemotherapy in advanced gastric cancer: results from a phase 3 randomized trial (AMC0101). Cancer Chemother Pharmacol. 2014 Jan;73(1):139-49. Epub 2013 Oct 27. link to original article PubMed
Fluorouracil monotherapy
back to top |
Regimen
Study | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|
Chang et al. 2002 | Phase III (C) | 1. 5-FU & Mitomycin 2. 5-FU, Doxorubicin, Mitomycin |
Seems not superior |
Preceding treatment
Chemotherapy
References
- Chang HM, Jung KH, Kim TY, Kim WS, Yang HK, Lee KU, Choe KJ, Heo DS, Bang YJ, Kim NK. A phase III randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil and mitomycin C versus 5-fluorouracil alone in curatively resected gastric cancer. Ann Oncol. 2002 Nov;13(11):1779-85. link to original article PubMed
Fluorouracil & Mitomycin
back to top |
Regimen
Study | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|
Allum et al. 1989 | Phase III (E) | Observation | Seems not superior |
Nakazato et al. 1994 | Phase III (C) | 5-FU, Mitomycin, PSK | Seems to have inferior OS |
Preceding treatment
Chemotherapy
References
- Allum WH, Hallissey MT, Kelly KA; British Stomach Cancer Group. Adjuvant chemotherapy in operable gastric cancer: 5 year follow-up of first British Stomach Cancer Group trial. Lancet. 1989 Mar 18;1(8638):571-4. link to original article PubMed
- Nakazato H, Koike A, Saji S, Ogawa N, Sakamoto J; Study Group of Immunochemotherapy with PSK for Gastric Cancer. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Lancet. 1994 May 7;343(8906):1122-6. link to original article PubMed
Metastatic or locally advanced disease, first-line
Best supportive care
back to top |
Regimen
Study | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|
Pyrhönen et al. 1995 | Phase III (C) | FEMTX | Inferior OS |
No antineoplastic treatment.
References
- Pyrhönen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer. 1995 Mar;71(3):587-91. link to original article link to PMC article PubMed
FAM
back to top |
FAM: Fluorouracil, Adriamycin (Doxorubicin), Mitomycin
Regimen
Study | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|
MacDonald et al. 1979 | Phase II | ||
Cullinan et al. 1985 | Phase III (C) | 1. 5-FU 2. FA |
Seems not superior |
Wils et al. 1991 | Phase III (C) | FAMTX | Inferior OS |
Kim et al. 1993 | Phase III (C) | 1. 5-FU 2. FP |
Seems not superior |
Kim et al. 1998 | Phase III (C) | FAM-P | Seems to have inferior OS |
Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.
Chemotherapy
References
- MacDonald JS, Woolley PV, Smythe T, Ueno W, Hoth D, Schein PS. 5-fluorouracil, adriamycin, and mitomycin-C (FAM) combination chemotherapy in the treatment of advanced gastric cancer. Cancer. 1979 Jul;44(1):42-7. link to original article PubMed
- Cullinan SA, Moertel CG, Fleming TR, Rubin JR, Krook JE, Everson LK, Windschitl HE, Twito DI, Marschke RF, Foley JF, Pfeifle DM, Barlow JF. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma: fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA. 1985 Apr 12;253(14):2061-7. link to original article PubMed
- Wils JA, Klein HO, Wagener DJ, Bleiberg H, Reis H, Korsten F, Conroy T, Fickers M, Leyvraz S, Buyse M, Duez N. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol. 1991 May;9(5):827-31. link to original article PubMed
- Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC, Kang YK, Shin DB, Kim HT, Kim HJ, Kang WK, Suh CI, Bang YJ. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer. 1993 Jun 15;71(12):3813-8. link to original article PubMed
- Kim SY, Park HC, Yoon C, Yoon HJ, Choi YM, Cho KS. OK-432 and 5-fluorouracil, doxorubicin, and mitomycin C (FAM-P) versus FAM chemotherapy in patients with curatively resected gastric carcinoma: a randomized Phase III trial. Cancer. 1998 Nov 15;83(10):2054-9. link to original article PubMed
FAMTX
back to top |
FAMTX: Fluorouracil, Adriamycin (Doxorubicin), MTX (Methotrexate)
Regimen
Study | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|
Wils et al. 1991 | Phase III (E) | FAM | Superior OS |
Kelsen et al. 1992 | Phase III (E) | EAP | Seems not superior |
Webb et al. 1997 | Phase III (C) | ECF | Inferior OS |
Vanhoefer et al. 2000 (EORTC 40902) | Phase III (C) | 1. ELF 2. FUP |
Seems not superior |
Chemotherapy
References
- Wils JA, Klein HO, Wagener DJ, Bleiberg H, Reis H, Korsten F, Conroy T, Fickers M, Leyvraz S, Buyse M, Duez N. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol. 1991 May;9(5):827-31. link to original article PubMed
- Kelsen D, Atiq OT, Saltz L, Niedzwiecki D, Ginn D, Chapman D, Heelan R, Lightdale C, Vinciguerra V, Brennan M. FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol. 1992 Apr;10(4):541-8. link to original article PubMed
- Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, Hughes M, Mansi J, Findlay M, Hill A, Oates J, Nicolson M, Hickish T, O'Brien M, Iveson T, Watson M, Underhill C, Wardley A, Meehan M. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997 Jan;15(1):261-7. link to original article PubMed
- Update: Waters JS, Norman A, Cunningham D, Scarffe JH, Webb A, Harper P, Joffe JK, Mackean M, Mansi J, Leahy M, Hill A, Oates J, Rao S, Nicolson M, Hickish T. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer. 1999 Apr;80(1-2):269-72. link to original article link to PMC article PubMed
- EORTC 40902: Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E, Planker M, Santos JG, Piedbois P, Paillot B, Bodenstein H, Schmoll HJ, Bleiberg H, Nordlinger B, Couvreur ML, Baron B, Wils JA. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol. 2000 Jul;18(14):2648-57. link to original article PubMed
FEMTX
back to top |
FEMTX: Fluorouracil, Epirubicin, MTX (Methotrexate)
Regimen
Study | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|
Pyrhönen et al. 1995 | Phase III (E) | Best supportive care | Superior OS |
Chemotherapy
References
- Pyrhönen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer. 1995 Mar;71(3):587-91. link to original article link to PMC article PubMed
Fluorouracil & RT
back to top |
RT: Radiation Therapy
Regimen
Study | Evidence |
---|---|
Moertel et al. 1969 | Non-randomized |
Chemotherapy
Radiotherapy
- Concurrent radiation therapy
References
- Moertel CG, Childs DS Jr, Reitemeier RJ, Colby MY Jr, Holbrook MA. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet. 1969 Oct 25;2(7626):865-7. link to original article PubMed